#363 Making a difference in indifference? Medications for apathy in dementia
CLINICAL QUESTION
In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
BOTTOM LINE
Methylphenidate may improve apathy scores by a small but potentially clinically meaningful amount compared to placebo (example: 5 points more on a 72-point scale) at ~12 weeks. Methylphenidate does not impact cognition in randomized, controlled trials (RCTs). Antipsychotics and antidepressants do not improve apathy compared to placebo.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Results statistically different unless indicated. Comparisons versus placebo.
- Two systematic reviews (4-7 RCTs, 346-1341 patients) from the last 5 years of treating apathy in mild-moderate Alzheimer’s dementia over 2-24 weeks.1,2
- Methylphenidate (immediate-release 10mg BID). Reporting most inclusive systematic review (4 RCTs, 346 patients):2
- Apathy (mix of informant- and clinician-rated)
- 72-point apathy scale (Baseline ~50; 3.3-point change clinically significant).3-6
- 6 point improvement versus 1 point (placebo) at ≤12 weeks.2
- 12-point apathy scale (Baseline ~7; 1-2 point change clinically significant).2,3,5,7
- No difference versus placebo at <12 weeks.2
- 4.5 point improvement versus 3.1 (placebo) at 24 weeks.2
- 72-point apathy scale (Baseline ~50; 3.3-point change clinically significant).3-6
- Clinicians’ global impression:
- Any improvement: 46% versus 34% (placebo).2
- Mini-mental state exam:
- No difference.2
- Any adverse events or dropouts due to adverse events:
- No difference.2
- Apathy (mix of informant- and clinician-rated)
- Antipsychotics (2 RCTs, 421-649 patients):1
- Apathy: No difference.
- Antidepressants:
- SSRIs (2 RCTs, 43-83 patients, neither required apathy diagnosis):1
- Apathy: Inconsistent results.8,9
- Bupropion (One RCT not in systematic reviews, 108 patients) versus placebo:10
- Apathy: No difference.
- Quality of Life (52-point scale): 1.2 points worse versus 0.4 better (placebo).
- SSRIs (2 RCTs, 43-83 patients, neither required apathy diagnosis):1
- Limitations: Small studies; one cross-over RCT (26 patients) negatively skewed meta-analyzed results;5 apathy a secondary outcome in antidepressant and antipsychotic RCTs; trial exclusion criteria (examples: cardiac abnormalities, uncontrolled hypertension, agitation) limit generalizability and safety data.
CONTEXT
- No improvement in apathy with cholinesterase inhibitors alone versus placebo,2 but 60-100% of RCT methylphenidate patients used cholinesterase inhibitors.1,2
- Methylphenidate associated with weight loss, behavioural changes, insomnia, and cardiovascular harms.11
- Depression and apathy often overlap and can be difficult to distinguish in practice.12
- Non-pharmacologic options include sensory stimulation (example music therapy) and pet therapy based on low-quality evidence of benefit.13
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
thank you for the info, helpful
Frustratingly poor results.
Good to know
I usually don’t have Trapo ready that is very high using these drugs.. Patience really do need to know the pros and cons of these drugs
Good talk
Good information. But not good news.